News Releases Year None2023202220212020 September 19, 2023 RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares View News September 14, 2023 RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering View News August 29, 2023 RayzeBio Appoints Christy Oliger to its Board of Directors View News June 21, 2023 RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting View News May 31, 2023 RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors View News May 22, 2023 RayzeBio to Present at Upcoming Medical Conferences View News March 21, 2023 RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer View News March 20, 2023 RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors View News January 4, 2023 RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 View News
Year None2023202220212020 September 19, 2023 RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares View News September 14, 2023 RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering View News August 29, 2023 RayzeBio Appoints Christy Oliger to its Board of Directors View News June 21, 2023 RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting View News May 31, 2023 RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors View News May 22, 2023 RayzeBio to Present at Upcoming Medical Conferences View News March 21, 2023 RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer View News March 20, 2023 RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors View News January 4, 2023 RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 View News
